In a heart failure model, Sonkawade et al. (2021) explored the therapeutic potential of small endogenous peptides in mitigating myocardial remodeling induced by galectin-3 overexpression [67], underscoring the promise of galectin-3 targeting for modulating pathological cardiac remodeling and improving diastolic function. This evidence concerns the gene LGALS3 and heart failure.